Compare iShares Core MSCI EAFE ETF (IEFA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.5 (market cap $189.19B), while Regeneron Pharmaceuticals Inc trades at $745.91 (market cap $76.14B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 2.5× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| IEFA | REGN | |
|---|---|---|
Market Cap | $189.19B | $76.14B |
Volume | 8,441,787 | 500,239 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $852.03 |
52-Week Low | $85.06 | $557.73 |
Typical Hold Time | 40 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.37, up 0.18% on the day, while technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The fund provides exposure to developed markets outside North America, holding $196 billion in assets. Recent news highlights its role in international diversification strategies and comparisons with competing ETFs like Schwab's SCHF and State Street's SPDW.
The outlook for IEFA is influenced by global market sentiment and interest rate uncertainty, offering diversification benefits but facing headwinds from geopolitical tensions. Key risks include concentration in developed economies and currency fluctuations. Analyst comparisons favor IEFA for its scale and dividend yield, though expense ratios and performance relative to peers remain considerations for investors.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
